126 Risk factors for febrile neutropemia among older patients with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) treated with anthracycline-based chemotherapy  by Morrison, V.A. et al.
$70 International Journal o[ In[ectious Diseases (2006) 10($1 ) Abstracts 
occurred 17.8 days after treatment. At[ but 1 
patient (93%) were neutropenic and neutropenia 
tasted 20.4 days before bacteremia. Twenty-six pa- 
tients (83.9%) had central venous catheters (CVC). 
At[ patients received antibiotics. Twenty-five pa- 
tients (80.6%) received carbapenems for a mean 
of 10.2 days (range 2-31 days) before onset of 
SM bacteremia. Almost at[ patients (93%) manifest 
infection with fever ranging from 37.6 to 40.2°C. 
Hypotension occurred in 5 patients (16.7%). Eigh- 
teen patients (58.1%) had symptoms related to: 
respiratory system (25.8%), skin (12.9%), CVC (6%) 
and gastrointestinal tract (16.1%); but SM was iso- 
lated only from the sputum of 4 patients and soft 
tissue of one. Complications were uncommon: 3 pa- 
tients (9.7%) had renal failure and 3 had respiratory 
compromise. The mean Apache-II score on day of 
bacteremia was 18.7. Twelve patients (38.7%) re- 
quired admission to ICU. CVC was removed in 13 pa- 
tients (41.9%). Twenty-four patients (77.4%) were 
treated with Bactrim and 2 (6.5%) had quino[ones. 
Five patients (16.1%) received inappropriate antibi- 
otics and at[ died. Mortality rate was 35.5% (11 
patients) but 3 deaths were deemed unrelated to 
SM infection. 
Conclusions: In hematology patients with pro- 
tonged hospitalization and neutropenia, SM bac- 
teremia should be considered when fever occurs 
despite broad-spectrum antibiotics. 
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Background: Therapy-related mye[osuppression is 
more common in older patients (pts) with DLBCL 
who are treated with regimens such as cyc[o- 
phosphamide, doxorubicin, vincMstine, prednisone 
(CHOP), with or without Mtuximab (R). FebM[e 
neutropenia (FN) may subsequently complicate the 
course of these patients. We examined the oc- 
currence of FN among a large series of older pts 
with DLBCL treated with either CHOP or R-CHOP 
on an onco[ogy intergroup tr ial  Risk factors for the 
occurrence of FN were identified among these pts. 
Objectives: To determine: (1) the incidence of FN 
in this pt population, and (2) risk factors that are 
predictive for the occurrence of FN in these pts. 
Methods: Pts >60 years of age with previously 
untreated DLBCL enrolled on a US onco[ogy coop- 
erative group trial (CALGB 9793/ECOG-SWOG 4494) 
were randomized to initial therapy with either 
(CHOP) or (R-CHOP). Data regarding the nadir neu- 
trophi[ counts and complications of FN were col- 
lected. The incidence of FN was ascertained, and 
baseline demographic features that were predic- 
tive for the occurrence of FN were identified. 
Results: Of the 632 pts enrolled on this trial, 
data was available for 520 pts with regard to 
nadir counts and the occurrence of FN. Among 
these 520 pts, 212 (41%) had at [east one episode 
of FN complicating their treatment course. Overall, 
FN occurred in 261/3216 cycles of therapy (8%). 
The median time to FN was Day 11, with 38% of 
at[ FN episodes occurring in cycle one of ther- 
apy. Of these 520 patients, 141 had at [east one 
hospitalization for FN, with a median period of 
hospitalization of five (range, 1-121) days. The 
occurrence of FN in cycle 1 of therapy was as- 
sessed by the study entry demographics, to identify 
risk factors for this complication. Analysis of only 
cycle 1 was undertaken in order to minimize the 
impact of dose reduction, dose delay, and mye[oid 
growth factor usage. Factors found to be predictive 
for cycle 1 FN included advancing age (evaluated as 
a continuous variable, p = 0.001), a tess favorable 
performance status (PS 2,3) (p=0.02), baseline 
hemoglobin of <12g/d[ (p= 0.0001), an elevated 
LDH (p=0.02), and a high-intermediate/high risk 
International Prognostic Index (IPI) score (p = 0.02). 
The presence of marrow involvement had no im- 
pact on the occurrence of FN. 
Conclusions: FN is a common occurrence among 
older pts with DLBCL receiving anthracyc[ine-based 
chemotherapy regimens. This complication tends 
to occur early in the treatment course. Risk fac- 
tors for the subsequent occurrence of FN include 
advancing age, poor PS, anemia, elevated LDH, and 
high-intermediate/high risk IPI score. Using these 
predictive factors, pt subgroups may be identified 
at baseline that wi[[ most benefit from mye[oid 
growth factor support with their therapy. 
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Introduction: Septicaemia due to unusual bacteria 
may be difficult to establish and often difficult to 
